Pathogenesis of chronic obstructive pulmonary disease
- PMID: 16267346
- PMCID: PMC2713323
- DOI: 10.1513/pats.200504-045SR
Pathogenesis of chronic obstructive pulmonary disease
Abstract
The current paradigm for the pathogenesis of chronic obstructive pulmonary disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Airspace inflammation appears to be different in susceptible smokers and involves a predominance of CD8+ T lymphocytes, neutrophils, and macrophages. Studies have characterized inflammation in the peripheral airspaces in different stages of disease severity. Two other processes have received considerable research attention. The first is a protease-antiprotease imbalance, which has been linked to the pathogenesis of emphysema. However, the hypothesis of an increased protease burden associated with functional inhibition of antiproteases has been difficult to prove and is now considered an oversimplification. The second process, oxidative stress, has a role in many of the pathogenic processes of chronic obstructive pulmonary disease and may be one mechanism that enhances the inflammatory response. In addition, it has been proposed that the development of emphysema may involve alveolar cell loss through apoptosis. This mechanism may involve the vascular endothelial growth factor pathway and oxidative stress.
Figures



Similar articles
-
[Pathogenesis of chronic obstructive pulmonary disease].Internist (Berl). 2006 Sep;47(9):885-6, 888-90, 892-4. doi: 10.1007/s00108-006-1691-y. Internist (Berl). 2006. PMID: 16845536 Review. German.
-
Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema.Respir Res. 2006 Mar 30;7(1):53. doi: 10.1186/1465-9921-7-53. Respir Res. 2006. PMID: 16571143 Free PMC article. Review.
-
Does Protease-Antiprotease Imbalance Explain Chronic Obstructive Pulmonary Disease?Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S130-7. doi: 10.1513/AnnalsATS.201504-196KV. Ann Am Thorac Soc. 2016. PMID: 27115947 Review.
-
Pathophysiology of airflow limitation in chronic obstructive pulmonary disease.Lancet. 2004 Aug 21-27;364(9435):709-21. doi: 10.1016/S0140-6736(04)16900-6. Lancet. 2004. PMID: 15325838 Review.
-
NO2-induced airway inflammation is associated with progressive airflow limitation and development of emphysema-like lesions in C57bl/6 mice.Exp Toxicol Pathol. 2005 Apr;56(6):341-50. doi: 10.1016/j.etp.2004.12.004. Exp Toxicol Pathol. 2005. PMID: 15945273
Cited by
-
Steroid Resistant CD8+CD28null NKT-Like Pro-inflammatory Cytotoxic Cells in Chronic Obstructive Pulmonary Disease.Front Immunol. 2016 Dec 19;7:617. doi: 10.3389/fimmu.2016.00617. eCollection 2016. Front Immunol. 2016. PMID: 28066427 Free PMC article. Review.
-
In Vivo Assessment of Mitochondrial Dysfunction in Clinical Populations Using Near-Infrared Spectroscopy.Front Physiol. 2017 Sep 14;8:689. doi: 10.3389/fphys.2017.00689. eCollection 2017. Front Physiol. 2017. PMID: 28959210 Free PMC article. Review.
-
Dual function inhibitors of relevance to chronic obstructive pulmonary disease.Bioorg Med Chem Lett. 2011 May 15;21(10):3177-80. doi: 10.1016/j.bmcl.2010.12.033. Epub 2010 Dec 10. Bioorg Med Chem Lett. 2011. PMID: 21511470 Free PMC article.
-
Unmasking the Silent Threat: Periodontal Health's Impact on COPD Severity and Hospitalization.J Pers Med. 2023 Dec 15;13(12):1714. doi: 10.3390/jpm13121714. J Pers Med. 2023. PMID: 38138940 Free PMC article.
-
Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease.Med Sci Monit. 2020 Oct 18;26:e925278. doi: 10.12659/MSM.925278. Med Sci Monit. 2020. PMID: 33070147 Free PMC article. Clinical Trial.
References
-
- Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–946. - PubMed
-
- Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709–721. - PubMed
-
- Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002;166:329–332. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials